Zai Lab Says Zoci Plus Atezolizumab Improves Response Rate in Phase 1 Lung Cancer Trial

07:41 AM EDT, 10/23/2026 (MT Newswires) -- Zai Lab (ZLAB) said Friday its experimental drug zocilurtatug pelitecan, or zoci, combined with atezolizumab achieved an 81.8% objective response rate in a phase 1 trial in patients with extensive-stage small cell lung cancer. The company said the investigational combination therapy also delivered an 81.9% six-month progression-free survival rate. Median progression-free survival had not been reached after a median follow-up of 10 months, implying that most patients continued to benefit from the treatment, the company said. Among patients who received the combination therapy with chemotherapy drug carboplatin, the objective response rate was 92.3%, with median progression-free survival of 8.4 months, Zai Lab said. Severe treatment-related side effects occurred in 76.9% of patients receiving the three-drug combination, compared with 21.2% of patients receiving the two-drug combination, Zai Lab said. The company said it plans to start a global phase 3 trial of zocilurtatug pelitecan combined with an immuno-oncology drug in extensive-stage small cell lung cancer by year-end 2026.